Q1 2019 13F Holders as of 3/31/2019
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
96M
-
Number of holders
-
168
-
Total 13F shares, excl. options
-
58M
-
Shares change
-
+7.7M
-
Total reported value, excl. options
-
$4.02B
-
Value change
-
+$543M
-
Put/Call ratio
-
0.36
-
Number of buys
-
112
-
Number of sells
-
-46
-
Price
-
$69.36
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q1 2019
194 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q1 2019.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 168 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 58M shares
of 96M outstanding shares and own 60.45% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (6.38M shares), Capital Research Global Investors (6.36M shares), Capital International Investors (5.57M shares), VANGUARD GROUP INC (4.89M shares), BlackRock Inc. (4.75M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.5M shares), FMR LLC (2.52M shares), STATE STREET CORP (1.92M shares), FIRST TRUST ADVISORS LP (1.86M shares), and Capital World Investors (1.81M shares).
This table shows the top 168 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.